Results 331 to 340 of about 656,371 (370)

Advances in the detection of minimal residual disease

Current Opinion in Hematology, 1997
The study of minimal residual disease (MRD) is an attempt to detect and define the significance of leukemia invisible to normal morphologic examination. In many circumstances the clinical significance of MRD detection is unclear, because the technical ability to detect and quantify it has outpaced studies demonstrating its clinical significance.
Jerry Radich, Blythe Thomson
openaire   +3 more sources

Minimal Residual Disease in Leukemia in Children

Annals of the New York Academy of Sciences, 1997
Many chromosomal translocations involved in leukemia have been defined at the molecular level in recent years. In addition to advancing the understanding of pathological mechanisms underlying the transformation process, the cloning and sequencing of the genes altered by the translocations have provided new tools for diagnosis and monitoring of patients.
Bernhard Kornhuber, E. Niegemann, U. Ebener, S. Wehner   +3 more
openaire   +2 more sources

Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis

Nature Cell Biology, 2022
Yingchi Zhang, Shicheng Wang, Jingliao Zhang, Chao Liu, Xinqi Li, Wenbo Guo, Yongjuan Duan, Xiaoyan Chen, Suyu Zong, Jiarui Zheng, Yixuan Wu, Xiaoli Chen, Xuelian Cheng, Yannicca W Y Chang, Yue Wang, F. Ding, Wenyu Yang, Xiaojuan Chen, Ye Guo, Li Zhang, Yumei Chen, Y. Zou, Xiaofan Zhu, Jin Gu, Tao Cheng   +24 more
semanticscholar   +1 more source

Minimal residual disease in acute leukaemia

European Journal of Cancer and Clinical Oncology, 1991
THE PERSISTENCE of leukaemic cells throughout remission of the disease is increasingly recognised by modern methods. In particular polymerase’ chain reaction methodology allows to demonstrate the persistence of a few leukaemic cells (0.004-2.6%) in bone marrow of some patients with complete remission (CR) of acute lymphoblastic leukaemia (ALL) [l]. The
Helga Schmetzer, H. H. Gerhartz
openaire   +3 more sources

Multiple Myeloma Minimal Residual Disease

2016
Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for potentially curable neoplasms such as some acute leukemias as well as chronic myeloid and lymphocytic leukemia. Although multiple myeloma (MM) remains as an incurable disease, around half of the patients achieve complete remission (CR), and recent data suggests ...
Jesús F. San Miguel, Bruno Paiva, Ramón García-Sanz   +2 more
openaire   +3 more sources

Evaluation of Minimal Residual Disease

2003
Intensive chemotherapy in acute lymphoblastic leukaemia leads to present relapse. Almost in all the cases relapse is due to original leukaemia clone proliferation and only in few cases different leukaemia clone is being formed. The main problem uncertainty wether a complete clinical remission was achieved.
R. Rokicka-Milewska, A. Wypych, J. Kulik, A. Raciborska, J. Siedlecki   +4 more
openaire   +2 more sources

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

The Lancet Oncology, 2016
Shaji K. Kumar, B. Paiva, K. Anderson, B. Durie, O. Landgren, P. Moreau, N. Munshi, S. Lonial, J. Bladé, M. Mateos, M. Dimopoulos, E. Kastritis, M. Boccadoro, M. Boccadoro, R. Orlowski, H. Goldschmidt, A. Spencer, J. Hou, W. Chng, S. Usmani, E. Zamagni, K. Shimizu, S. Jagannath, H. Johnsen, E. Terpos, A. Reiman, R. Kyle, P. Sonneveld, P. Richardson, P. McCarthy, H. Ludwig, Wenming Chen, M. Cavo, J. Harousseau, S. Lentzsch, J. Hillengass, A. Palumbo, A. Órfão, S. Rajkumar, J. Miguel, H. Avet-Loiseau   +40 more
semanticscholar   +1 more source

Liquid biopsy and minimal residual disease — latest advances and implications for cure

Nature Reviews Clinical Oncology, 2019
K. Pantel, C. Alix-Panabières
semanticscholar   +1 more source

Minimal Residual Disease in Neuroblastoma

2015
Detecting minimal amounts of tumor cells in bone marrow, peripheral blood, putative metastatic sites, lymph nodes or in other tissues, compartments or body fluids has become a major goal in cancer ...
openaire   +2 more sources

Monitoring minimal residual disease in AML

Cytotherapy, 1999
There have been a number of publications that describe the clinical monitoring of acute leukemia patients for residual leukemia cells. Almost all of them have been focused on ALL. The phenotype of ALL appears to be quite stable. In contrast, the relapse phenotype for AML is almost always different from the phenotype found in the diagnostic specimen ...
openaire   +3 more sources